According to the latest unaudited financial results approved by the Board of Directors on August 13, 2026, Cresanto Global reported a standalone net loss of ₹5.88 lakh in Q1 FY27. This represents a significant 75% reduction from the net loss of ₹23.54 lakh recorded in the preceding quarter ended March 31, 2026. The company maintained nil revenue from operations during both quarters, continuing its operational status without core business income.
As reported in the latest financial results, Cresanto Global reported no sales during both Q1 FY27 and Q4 FY25. The company's total income remained at nil for Q1 FY27, continuing the trend from Q4 FY25 where only minimal other income was recorded. The absence of revenue generation across both periods indicates the company's operational status during these quarters, with the company continuing to operate without core business income.
The 75% reduction in net loss was primarily driven by elimination of finance costs and substantial reduction in employee benefits expenses. Employee benefits expenses stood at ₹0.46 lakh, down from ₹3.40 lakh in the previous quarter. Finance costs were nil in Q1 FY27, compared to ₹15.86 lakh in Q4 FY25. Other expenses were ₹5.42 lakh, compared to ₹4.44 lakh in Q4 FY25. The total expenses declined substantially, driving the improvement in the bottom line despite maintaining zero revenue generation.
The unaudited financial results were reviewed by K T P S & Co., Chartered Accountants, in accordance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company, formerly known as Raymed Labs Limited, continues to operate without core business income, relying on cost containment measures to reduce quarterly losses while maintaining its regulatory compliance standards.
